Zacks Research Weighs in on Cencora's Q1 Earnings (NYSE:COR)

Cencora, Inc. (NYSE:COR - Free Report) - Equities researchers at Zacks Research increased their Q1 2025 EPS estimates for Cencora in a report issued on Wednesday, November 27th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $3.42 per share for the quarter, up from their prior estimate of $3.28. The consensus estimate for Cencora's current full-year earnings is $14.93 per share. Zacks Research also issued estimates for Cencora's Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.82 EPS, Q3 2026 earnings at $3.85 EPS, Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $16.17 EPS and FY2027 earnings at $17.41 EPS.

A number of other equities analysts have also issued reports on COR. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research report on Monday, October 7th. Evercore ISI upped their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 21st. Bank of America reissued a "neutral" rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $271.20.

Cencora Stock Down 0.8 %

Shares of NYSE COR traded down $2.10 during trading hours on Monday, hitting $249.45. The stock had a trading volume of 378,828 shares, compared to its average volume of 1,390,765. The company has a market capitalization of $49.15 billion, a P/E ratio of 33.22, a P/E/G ratio of 1.67 and a beta of 0.44. The firm's 50-day moving average price is $234.91 and its two-hundred day moving average price is $232.61. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora has a 52 week low of $195.83 and a 52 week high of $253.27.

Institutional Trading of Cencora

Hedge funds and other institutional investors have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. acquired a new position in Cencora during the 1st quarter valued at about $411,000. Cetera Advisors LLC purchased a new position in Cencora during the first quarter worth about $2,091,000. EverSource Wealth Advisors LLC bought a new stake in Cencora in the 1st quarter worth about $325,000. GAMMA Investing LLC increased its stake in Cencora by 35.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,762 shares of the company's stock valued at $622,000 after buying an additional 723 shares during the last quarter. Finally, DNB Asset Management AS lifted its position in shares of Cencora by 13.4% during the 2nd quarter. DNB Asset Management AS now owns 29,007 shares of the company's stock worth $6,535,000 after buying an additional 3,432 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares of the company's stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 93,018 shares of company stock valued at $22,478,942. Corporate insiders own 15.80% of the company's stock.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. This is a boost from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.